Osteoarthritis Therapeutics Market to Reach $24,744.3 Million by 2035, Driven by Rising Arthritis-Disability

Osteoarthritis Therapeutics market was valued at $11,200.0 million in 2025 and is projected to reach $24,744.3 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026-2035). The growing burden of arthritis-related disability is a critical driver shaping demand in the osteoarthritis therapeutics market, as functional impairment significantly increases the need for sustained medical intervention. According to US Centers for Disease Control and Prevention, an estimated 58.5 million adults aged 18 years and older in the US have arthritis, underscoring the scale of the affected population. Of these individuals, 25.7 million report arthritis-attributable activity limitations, reflecting substantial disease impact on daily functioning and quality of life. Projections further indicate that by 2040, approximately 34.6 million adults with arthritis are expected to experience activity limitations, indicating a worsening disability burden over time.

Browse the full report description of “Global Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2026-2035” at https://www.omrglobal.com/industry-reports/osteoarthritis-therapeutics-market

This rising prevalence of functional impairment reinforces demand for long-term pharmacologic therapies aimed at pain control, inflammation reduction, and mobility preservation. As activity limitations progress, patients typically require more intensive and prolonged treatment regimens, increasing lifetime therapeutic utilization. These trends directly support market expansion for osteoarthritis drugs, including non-steroidal anti-inflammatory drugs, injectable therapies, and emerging disease-modifying agents. Additionally, growing disability prevalence encourages earlier treatment initiation and closer disease monitoring, extending treatment duration.

Innovation Leaders Transforming the Osteoarthritis Therapeutics Market

The key players in the osteoarthritis therapeutics market include Pfizer Inc., Bayer AG, Sanofi, Haleon plc, Kenvue Inc., among others. These companies are driving innovation in the global osteoarthritis therapeutics market through the development of disease-modifying drug candidates, advanced biologics, and novel intra-articular therapies aimed at slowing joint degeneration and improving long-term function. Ongoing advances in targeted mechanisms of action, combination approaches, and clinical trial design are supporting evolving treatment needs, unmet disease-modification goals, and improved patient outcomes across global healthcare markets.

• In January 2026, 4Moving Biotech received US FDA clearance for its investigational new drug application for 4P004, allowing the company to expand its Phase 2a INFLAM MOTION trial for osteoarthritis into the US. The therapy aims to modify disease progression by targeting multiple biological markers in the joint, potentially slowing structural damage while improving function, marking a key step toward developing the first disease-modifying treatment for osteoarthritis.

• In July 2025, Johnson & Johnson MedTech a strategic co-promotion agreement with Pacira BioSciences, Inc., the industry leader in the delivery of innovative, non-opioid pain therapies. The agreement expands the Company’s Early Intervention portfolio with ZILRETTA (triamcinolone acetonide extended-release injectable suspension) an extended-release injectable for treatment of pain related to osteoarthritis (OA) of the knee.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Anatomy
  • By Drug Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Pfizer Inc., Bayer AG, Sanofi, Haleon plc, Kenvue Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Osteoarthritis Therapeutics Market Report Segment

By Anatomy

• Knee Osteoarthritis
• Ankle and Foot Osteoarthritis
• Hip Osteoarthritis
• Shoulder Osteoarthritis
• Spine Osteoarthritis
• Others

By Drug Type

• NSAIDs
• Corticosteroids
• Analgesics
• Opioid Analgesics
• Biologics
• Viscosupplementation Agents
• Regenerative Medicine/ Therapies
• Others

Global Osteoarthritis Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/osteoarthritis-therapeutics-market